3billion recently held symposiums to accelerate the diagnosis of rare diseases in Malaysia. 3billion is a Korean biotechnology company that provides genetic testing services for diagnosing rare diseases. The tour’s purpose was to go beyond being a simple service provider and interacting more closely with our collaborators, whose purpose is the diagnosis of rare diseases. It was carried out to find solutions alongside the local medical professionals actively.

For four days, 3billion Team met more than 200 medical professionals across nine medical institutions to introduce 3bilion’s services and discuss how we can help diagnose rare genetic disease patients together.

In particular, Hospital Kuala Lumpur (HKL), University Malaya Medical Center (UMMC), and Penang General Hospital (Hospital Pulau Pinang) with their key medical staff have been establishing and developing management systems in Malaysia for rare disease patients. These institutions have been collaborating closely with 3billion to accomplish this feat.

Sook-jin Lee, 3billion’s CBO (Chief Business Officer), said, “After coming in person, I was able to understand firsthand not only the concerns of the medical professionals but also the patients much more deeply. Recently, genomic analysis technology has been developing rapidly, but it still takes time for new technology to be fully adopted. To reduce adoption times, diagnosis companies should consider the perspectives of both medical professionals and patients. The tour was a great opportunity to understand the Malaysian medical system fully and to help find answers to what needs to be done to improve diagnosis of rare diseases.”

3billion plans to improve their services and increase user convenience by listening to the voices of medical professionals. In addition, they have recently announced plans to accelerate the diagnosis of rare diseases by conducting webinars and educational programs for medical professionals to help them further understand genomic diagnostics.